BioVie Inc. (BIVI)
NASDAQ: BIVI · IEX Real-Time Price · USD
0.487
-0.002 (-0.39%)
At close: Apr 19, 2024, 4:00 PM
0.490
+0.004 (0.72%)
After-hours: Apr 19, 2024, 7:58 PM EDT

Company Description

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States.

Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.

The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.

BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BioVie Inc.
BioVie logo
Country United States
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Cuong Viet Do M.B.A.

Contact Details

Address:
680 W Nye Lane, Suite 201
Carson City, Nevada 89703
United States
Phone 775-888-3162
Website bioviepharma.com

Stock Details

Ticker Symbol BIVI
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001580149
CUSIP Number 09074F207
ISIN Number US09074F2074
Employer ID 46-2510769
SIC Code 2834

Key Executives

Name Position
Cuong Viet Do M.B.A. President, Chief Executive Officer and Director
Joanne Wendy Kim CPA Chief Financial Officer, Treasurer and Corporate Secretary
Dr. Joseph M. Palumbo M.D. Executive Vice President of Research & Development and Chief Medical Officer
Clarence N. Ahlem Senior Vice President of Operations
Dr. Penelope Markham Ph.D. Senior Vice President of Liver Disease Program
Denise Smith Senior Vice President of Manufacturing and Development
Dr. Christopher L. Reading Ph.D. Senior Vice President of Alzheimer's Disease Program
Sarah Overton Hoit Chief Social Impact Officer

Latest SEC Filings

Date Type Title
Apr 19, 2024 8-K Current Report
Mar 11, 2024 8-K Current Report
Mar 6, 2024 8-K Current Report
Mar 4, 2024 8-K/A [Amend] Current report
Mar 4, 2024 424B5 Filing
Mar 4, 2024 8-K Current Report
Mar 1, 2024 424B5 Filing
Mar 1, 2024 8-K Current Report
Feb 13, 2024 10-Q Quarterly Report
Jan 25, 2024 8-K Current Report